Price T Rowe Associates Inc Harmony Biosciences Holdings, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 14,877 shares of HRMY stock, worth $506,859. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,877

Previous 14,692 1.26%

Holding current value

$506,859

Previous $444,000 34.23%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$30.0 - $39.95 $5,550 - $7,390	185 Added 1.26%	14,877 $596,000
Q2 2024 Aug 14, 2024	BUY	$28.81 - $33.01 $13,627 - $15,613	473 Added 3.33%	14,692 $444,000
Q1 2024 May 15, 2024	BUY	$29.93 - $35.06 $35,945 - $42,107	1,201 Added 9.23%	14,219 $478,000
Q4 2023 Feb 14, 2024	BUY	$19.2 - $33.78 $11,904 - $20,943	620 Added 5.0%	13,018 $421,000
Q3 2023 Nov 14, 2023	BUY	$31.89 - $39.03 $22,865 - $27,984	717 Added 6.14%	12,398 $407,000
Q2 2023 Aug 14, 2023	BUY	$30.5 - $37.4 $49,654 - $60,887	1,628 Added 16.19%	11,681 $412,000
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $13,983 - $24,479	454 Added 4.73%	10,053 $329,000
Q4 2022 Feb 14, 2023	BUY	$45.4 - $60.91 $16,207 - $21,744	357 Added 3.86%	9,599 $529,000
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $73,184 - $96,483	1,740 Added 23.19%	9,242 $410,000
Q2 2022 Aug 15, 2022	BUY	$33.54 - $52.15 $14,656 - $22,789	437 Added 6.19%	7,502 $366,000
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $16,570 - $25,565	500 Added 7.62%	7,065 $344,000
Q4 2021 Feb 14, 2022	BUY	$34.09 - $43.91 $223,800 - $288,269	6,565 New	6,565 $280,000

Others Institutions Holding HRMY

# of Institutions

242

Shares Held

45.2M

Call Options Held

108K

Put Options Held

49.2K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.02B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Harmony Biosciences Holdings, Inc. Transaction History